Abstract Carcinoembryonic antigen (CEACAM5) is commonly overexpressed in human colon cancer. Several antigenic peptides recognized by cytolytic CD8+ T-cells have been identiWed and used in colon cancer phase-I vaccination clinical trials. The HLA-A*0201-binding CEA [694][695][696][697][698][699][700][701][702] peptide was recently isolated from acid eluted MHC-I associated peptides from a human colon tumor cell line. However, the immunogenicity of this peptide in humans remains unknown. We found that the peptide CEA 694-702 binds weakly to HLA-A*0201 molecules and is ineVective at inducing speciWc CD8+ T-cell responses in healthy donors. Immunogenic-altered peptide ligands with increased aYnity for HLA-A*0201 were identiWed. Importantly, the elicited cytolytic T lymphocyte (CTL) lines and clones cross-reacted with the wild-type CEA 694-702 peptide. Tumor cells expressing CEA were recognized in a peptide and HLA-A*0201 restricted fashion, but high-CEA expression levels appear to be required for CTL recognition. Finally, CEA-speciWc T-cell precursors could be readily expanded by in vitro stimulation of peripheral blood mononuclear cell (PBMC) from colon cancer patients with altered CEA peptide. However, the CEAspeciWc CD8+ T-cell clones derived from cancer patients revealed low-functional avidity and impaired tumor-cell recognition. Together, using T-cells to demonstrate the processing and presentation of the peptide CEA694-702, we were able to corroborate its presentation by tumor cells. However, the low avidity of the speciWc CTLs generated from cancer patients as well as the high-antigen expression levels required for CTL recognition pose serious concerns for the use of CEA694-702 in cancer immunotherapy.
Introduction
Carcinoembryonic antigen (CEA), also designated CD66e or CEACAM5, belongs to a heterogeneous protein family that shares common immunoglobulin domains [13] . CEA confers homophilic and heterophilic cell adhesion and may contribute to the metastatic progression of tumors [16] . CEA has also been reported to block cell diVerentiation and to cooperate with other molecules in cellular transformation [8, 34] .
The CEA has been proposed as a potential target antigen for immunotherapy because it is overexpressed by most colorectal, gastric, and pancreatic carcinomas, by 50% of breast cancers, and by 70% of non-small cell lung carcinomas [5, 38] . In contrast, CEA is expressed at lower levels in normal epithelial cells and fetal tissue [23] . Increased levels of soluble CEA can be detected in the serum from most patients with CEA-positive tumors, which allows the use of CEA as surrogate marker for disease progression and response to therapy [12, 20] .
Numerous clinical studies have been performed in the last few decades targeting CEA for immunotherapy of colorectal carcinoma. CEA-derived antigens were delivered as recombinant vectors, peptides, or full-length protein (for review see [5, 6] ). Overall, variable proportions of patients had positive DTH responses upon vaccination, and although the majority of vaccinated patients have been shown to mount CEA-speciWc T-cell and antibody responses, clinical results have been disappointing. Moreover, only rarely the CEA-speciWc cytolytic T lymphocyte (CTL) responses correlated with decreased CEA serum levels or clinical responses. Of note, one study testing immunization with autologous Flt3L-induced dissociation complex (DCs) pulsed with the HLA-A*0201-restricted peptide CEA-CAP1-6D, an analog of CEA [605] [606] [607] [608] [609] [610] [611] [612] [613] peptide (YLSGANLNL), reported two complete clinical responses out of 12 metastatic colorectal cancer patients [10] .
A novel HLA-A*0201-restricted peptide was recently identiWed in eluted peptides from MHC class-I molecules of a human colon cancer cell line (SW1116) and fresh human colon cancer tissue [33] . From a list of CEA-derived peptides predicted to be potential binders of HLA-A*0201, the authors could only identify one new single peptide derived from CEA, which was the peptide CEA [694] [695] [696] [697] [698] [699] [700] [701] [702] (GVLVGVALI). Interestingly, both the cell line and the fresh tumor tissue presented the same peptide. This biochemical approach is independent of the preexistence of tumor-speciWc CD8+ T-cells, commonly used for the identiWcation of novel processed and presented HLA-restricted epitopes [3] . Although the authors demonstrated the processing and presentation of the CEA 694-702 peptide, no immunogenicity data have been reported [33] .
In this manuscript, we evaluated the antigenicity and immunogenicity of the CEA 694-702 peptide. We found that the native CEA [694] [695] [696] [697] [698] [699] [700] [701] [702] peptide is poorly immunogenic in healthy donors. In addition, this peptide binds weakly to the HLA-*0201 (HLA-A2) molecule. In contrast, analogs with improved binding to HLA-A*0201 molecules were immunogenic. CD8+ T-cell clones cross-reactive with analog and native peptides were of low to intermediate avidity.
Moreover, these clones recognized tumor cells with high-CEACAM5 expression, conWrming that CEA [694] [695] [696] [697] [698] [699] [700] [701] [702] peptide is processed by human tumor cell lines and recognized under certain circumstances. Finally, we found that CEA 694-702 -speciWc T-cell responses can be induced in peripheral blood mononuclear cell (PBMC) in colon cancer patients. However, in contrast to healthy donor-derived CTL, CD8 + T-cell clones generated from cancer patients had lower avidity and were unable to recognize CEAexpressing tumor cells.
Materials and methods

Synthesis of peptides
Peptides described in Table 2 as well as HIVpol 589-597 (IVGAETFYV), FluMA 58-66 (GILGFVFTL), and NY-ESO-1 157-165 (SLLMWITQA) were synthesized in an automated peptide synthesizer 432A (Applied Biosystems, Weiterstadt, Germany) following the N-(9-Xuorenyl)methoxycarbonyl/tert-butanol strategy. Synthesis products were analyzed by HPLC (Varian star; Zinsser, Munich, Germany) and MALDI-TOF mass spectrometry (G2025A; HewlettPackard, Waldbronn, Germany). Peptides were puriWed by preparative HPLC and dissolved in DMSO to a Wnal concentration of 10 mM.
Patients
Peripheral blood mononuclear cells of HLA-A*0201 colon cancer patients were obtained after informed consent. The study protocol was approved by the Ludwig Institute for Cancer Research protocol review committee, as well as by the medical and ethical committees of the University Hospital (Lausanne, Switzerland). All patients had primary colorectal adenocarcinomas and had not been enrolled in any adjuvant therapy at the time of blood sampling.
Major histocompatibility complex/peptide multimers and monoclonal antibodies Phycoerythrin-labeled HLA-A2/peptide multimers [1] were synthesized around CEA 694-702 peptide and designed peptide analogs. The cut-oV value for detection of antigen-speciWc
CD8
+ T-cells with HLA-A2/peptide multimers was determined by Xow cytometry analysis of CD8 + T-cells from HLA-A2 + and HLA-A2 ¡ human healthy donors stained with the multimers. Monoclonal antibodies (mAbs) were from Becton Dickinson, San Jose, CA, USA. Dead cells, in all situations, were electronically excluded by Propidium Iodine staining.
Cell lines
Human colon cell line SW1116 was the kind gift from H.G. Rammensee (Universitaet Tuebingen, Tuebingen, Germany). Human colon cell lines SW403, SW480, COLO201, SW620, LOVO, HCT-116, T84; gastric cancer cell line KATOIII; and NK-sensitive cell line K562 were bought from ATCC, Molsheim, France. Na8MEL was the kind gift from Francine Jotereau (INSERM, Nantes, France) and Me 290 melanoma cell line was generated from a melanoma patient (LAU 203) by Donata Rimoldi (Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland- [40] ). All tumor cell lines were used in CTL assays at exponential phase of cell culture growth and at »80% conXuence.
Measurement of peptide relative aYnity to HLA-A*0201
The protocol used was as previously described [39] and applied elsewhere [2, 3, 9] . BrieXy, T2-cells were incubated at 37°C for 16 h with peptides at concentrations ranging from 100 to 0.1 M, and then stained with BB7.2 mAb [25] to quantify the surface expression of HLA-A*0201. For each peptide concentration, HLA-A2-speciWc staining was calculated as the % of the staining obtained in the presence of 100 M of the reference peptide (HIVpol 589-597 ; IVGAETFYV). The RA score is the ratio of the concentration of each peptide to the concentration of the reference peptide that induces 20% of the HLA-A2 expression; the lower the RA is, the stronger the peptide binds to HLA-A2. The mean RA for each peptide was determined from at least three independent experiments. In all experiments, 20% of HLA-A2 expression using the reference peptide was obtained at concentrations of 1-3 M.
Assessment of peptide/HLA-A*0201 complex stability As previously described [39] , T2-cells were incubated overnight with 100 M of each peptide at 37°C in serumfree medium. The cells were then incubated with Brefeldin A (Sigma-Aldrich, St. Louis, MO, USA) at 10 g/ml for 1 h, washed, incubated at 37°C during 0, 1, 2, 4, or 6 h in the presence of Brefeldin A (50 ng/ml) and Wnally stained with BB7.2 moAb. For each time point, peptide-induced HLA-A2 expression was calculated as: mean Xuorescence of peptide-incubated T2-cells-mean Xuorescence of T2-cells treated in similar conditions in the absence of peptide. DC50 DC was deWned as the time required for the loss of 50% of the HLA-A*0201/peptide complexes stabilized at t = 0 h.
In vitro expansion of circulating antigen speciWc CD8 + T lymphocytes Peripheral blood mononuclear cells were isolated by FicollHypaque (Beckman-Coulter, Fullerton, CA, USA) from the blood of human healthy donors. For generation of autologous dendritic (DC) cells, PBMCs were allowed to adhere into Petri-dishes during 2 h at 37°C. Adherent cells were incubated with 700 IU/ml of Granulocyte-Macrophage Colony Stimulating Factor (R&D Systems, Minneapolis, MN, USA) and 1,000 IU/ml of IL-4 (R&D Systems) in CTL culture medium [RPMI 1640 (Invitrogen, Basel, Switzerland ), 8% pooled human serum, Penicilin/Streptavidin (Invitrogen), 50 M -mercaptoethanol (Sigma)]. CD8+ T-cells were puriWed from non-adherent PBMC by negative selection using immunomagnetic beads (Miltenyi, Bergisch Gladbach, Germany) following the manufacturer's instructions. For priming, DC were extensively washed and pulsed at least during 2 h with 10 M of peptide in serum-free media. Pulsed DCs were later maturated with LPS (Sigma) at 5 g/ml overnight. Co-culture of DCs with autologous CD8+ -puriWed T-cells was done at 1:5 ratio in CTL culture medium. IL-2 (Proleukin, Roche, Switzerland) at 20 IU/ml was added at day 2 and the culture medium was renewed every other day. At days 7 and 14, CTLs were restimulated with overnight peptide-pulsed (10 M) T2-cells, which were lethally irradiated. The cultures were evaluated at day 21 for the presence of peptide-speciWc expanded CD8+ Tcells. In vitro stimulation of PBMC with CEA-derived peptides in microcultures was performed as previously described [21] using freshly isolated PBMCs at 0.2 £ 10 6 cells/well (96 U-bottom plate) (FALCON, Franklin Lakes, NJ, USA) in CTL culture medium in the presence of 10 M of peptide. IL-2 was added at day 2 at 1,000 IU/ml. The medium was changed every other day and the induction of speciWc CD8 + T-cells was evaluated at day 10.
Multimer-guided cell sorting and cloning
The expansion of CEA peptide-speciWc CD8+ T-cells stimulated by co-culture with autologous DC or in the peptide-stimulated PBMC microcultures was evaluated by multicolor Xow cytometry of day 21 or 10, respectively, employing peptide-MHC multimers. The cultures were harvested and washed in PBS 0.2% BSA, 50 mM EDTA (Facs buVer). PE-conjugated multimers were incubated at room temperature during 1 h in FACS buVer. After washing, cells were incubated with FITC-conjugated anti-human CD8 mAb at 4°C during 20 min. Cells were immediately acquired in a FACsVantage cell sorter. Multimer + CD8 + cells were electronically gated and sorted at 4°C. Sorted cells were promptly placed in culture in CTL culture medium with 150 IU/ml of rhIL-2 overnight. The next day, sorted cells were cloned by co-culture in limiting dilution conditions (0.3 cells/well) in NUNCLON plates (NUNC, Roskilde, Denmark) with 10 4 irradiated allogenic PBMC, 150 IU/ml of IL-2, and 1 g/ml of phytohemagglutinin-leukoagglutinin (PHA-L) (REMEL, Dartford, UK). Proliferating wells were screened after 7-9 days of culture and expanded to 96 U-bottom plate wells. Cells were then restimulated with irradiated allogenic PBMCs, IL-2, and PHA-L as above. Cultures were replenished with media and split into new plates as required. CTL clones generated were evaluated with multimers for TCR speciWcity and later for functional antigen-triggered cytolitic activity.
Chromium release-based cytolytic assay Cytolytic activity was assessed using a 4 h chromium release assay. To evaluate the relative avidity for the antigen ligand of the CTL clones generated upon multimerguided cell sorting, radiolabeled T2-cells were plated in 96 V-bottom plates and pulsed with a range of peptide concentrations (10 ¡5 to 10 ¡14 M). Cells were incubated with peptide at least 1 h before addition of cloned CTL at an eVector to target cell ratio of 10:1. In tumor recognition assays, "hot" targets were co-cultured with T-cell clones at diVerent eVector to tumor cell ratios. About 50 IU/ml of IFN-(R&D Systems) was added to tumor cells culture medium during 72 h prior to some tumor recognition assays. Na 51 Cr released in the media was quantiWed using LumaPlate-96 plates (PerkinElmer, Wellesley, MA, USA) and a TopCount--counter (PerkinElmer).
Reverse-transcription and semi-quantitative PCR Total RNA was extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany). About 1 g RNA was then reverse-transcribed to cDNA using M-MLV reverse transcriptase (Invitrogen). The following primers were used for semiquantitative polymerase chain reaction (PCR): -actin forward 5Ј-GGC ATC GTG ATG GAC TCC G-3Ј reverse 5Ј-GCT GGA AGG TGG ACA GCG A-3Ј; CEACAM3 forward 5Ј-TTG CCA AAA CTG GAA GAA CC-3Ј reverse 5Ј-AGC CAC TTC TGC TTT GTG GT-3Ј; CEA-CAM4 forward 5ЈCGC ATA CAG TGG TCG AGA GA-3Ј reverse 5Ј-TGG GAC GTT GTT TTG GTG TA-3Ј; CEA-CAM5 forward 5Ј-AAC CCA GAA CCC AGT GAG TG-3Ј reverse 5Ј-ATT GCT GGA AAG TCC CAT TG-3Ј.
Thermocycling conditions for CEACAM3, CEACAM4, and CEACAM5 were the following: 94°C, 15Љ; 25 £ (94°C 15Љ, 60°C 30Љ, 72°C 60Љ), 72°C 10Ј, 4°C pause. All reactions were performed in a T3 thermocycler (Biometra, Göttingen, Germany). PCR products were visualized by electrophoresis on agarose gel stained with ethidium bromide.
Results
Peptide CEA 694-702 is poorly immunogenic and displays low-binding activity to HLA-A*0201 molecules Labeling of PBMC samples from Wve HLA-A2+ healthy donors with A2/CEA 694-702 multimers in conjunction with anti-hCD8 antibody did not detect CEA 694-702 -speciWc T-cells (not shown). The threshold of detection could be Wxed at 0.07 § 0.02%-a value comparable to the values determined for other HLA-A2/peptide multimers used in our laboratory [37] . To probe the potential immunogenicity of peptide CEA 694-702 , we performed multiple in vitro stimulations of PBMCs from HLA-A*0201 + healthy donors and evaluated the presence of expanded peptide-speciWc CD8 Table 1 , the peptide CEA 694-702 did not generate detectable peptide-speciWc responses either after stimulation of PBMC with peptide and IL-2, or after multiple stimulations of puriWed CD8
+ T-cells with autologous peptide-pulsed dendritic cells.
A major determinant of peptide immunogenicity is its ability to stably bind to the presenting MHC molecule. Therefore, we determined CEA 694-702 peptide's aYnity and stability to HLA-A*0201 molecules using in silico and in vitro methods. As shown in Table 2 , the native CEA 694-702 peptide was predicted to have relatively low-aYnity scores when compared with a known viral epitope (HIVpol 589-597 , a good binder to HLA-A*0201) [39] . These predictions were conWrmed experimentally ( Table 2) . CEA 694-702 presents low capacity to stabilize cell surface HLA-A*0201 on T2-cells: it presented bad relative aYnity scores (RA > 10) and formed short lived complexes with HLA-A2 (t < 1 h).
Analogs of peptide CEA 694-702 have higher HLA-A*0201-binding capacities Because of the low aYnity of peptide CEA 694-702 , we designed three peptide analogs incorporating canonical HLA-A*0201 anchor residues (leucine at position 2 and/or valine at position 9). These peptides with sequences GLLVG-VALI, GVLVGVALV, and GLLVGVALV will be termed CEA694L2, CEA694V9, and CEA694L2V9, respectively. When the canonical HLA-A*0201 anchor motifs were introduced into the peptide sequence, their binding to HLA-A2 improved substantially as reXected by their enhanced ability to stabilize surface HLA-A2 expression in T2-cells (Table 2) . Moreover, CEA694L2, CEA694V9, and CEA694L2V9 analog peptides showed relative aYnity values 8-24 times higher than the wild-type peptide. The CEA694L2V9 variant presented the highest aYnity. Moreover, the CEA694L2V9 and CEA694V9 and to a lesser degree CEA694L2 peptide analogs substantially increased the stability of surface HLA-A2 expression at 37°C. In summary, CEA 694-702 peptide analogs have increased aYnity to HLA-A*0201 MHC class-I allele as compared to the wild-type peptide. CEA694L2 and CEA694L2V9 were the analogs that elicited more frequently detectable responses and independent of the method of in vitro expansion used.
Cloned CD8 + T-cells speciWc for the CEA694L2 analog eYciently cross-recognize the native CEA 694-702 peptide Using multimer-guided cell sorting and limiting dilution techniques, we isolated CD8 + T-cell clones speciWc for each of the CEA 694-702 peptide analogs. Only stable CD8 + T-cell clones were obtained upon sorting with A2/ CEA694L2 multimers (n = 11). Other clones isolated with A2/CEA694, A2/CEA694V9, or A2/CEA694L2V9 multimers were not speciWc or with very limited proliferative capacity and, therefore, detailed characterization was not possible. Thus, all functional assays were conducted using CTL clones obtained with CEA694L2-speciWc multimers. We Wrst assessed the level of cross-reactivity between native (CEA 694-702 ) and the analog (CEA694L2) peptides by staining the CEA694L2-speciWc CD8 + T-cell clones with HLA-A2 multimers incorporating either CEA 694-702 or CEA694L2 peptides. As shown in Fig. 2a , the clone no. R1, representative of all clones analyzed, is eYciently labeled by the two multimers, albeit the intensity of the Xuorescent signal was higher when stained with the A2/CEA694L2 speciWc multimer. This observation suggests the higher TCR avidity for the peptide analog-MHC complex [45] .
We then assessed the level of functional cross-reactivity between the CEA 694-702 and CEA694L2 peptides in a chromium release assay. As depicted in Fig. 2b , the representative T-cell clone no. R1 recognized and lysed peptide sensitized HLA-A2 + T2-cells eYciently. Half maximal lysis was observed at analog peptide concentrations ranging between 1 and 10 nM for all the clones tested (n = 11).
Recognition of the native peptide was equally eYcient. We also extended the analysis of CEA antigen cross-reactivity to naturally occurring CEA 694-702 peptides present in other CEA family members. These include GVLVGVALV, which in fact is identical to one of the designed peptide analogs described above-CEA694V9 (CEACAM3 and CEACAM4), GVVALVALI (CEACAM1), GVLARVALI (CEACAM6 and CEACAM8), and GVLAGMALI (CEA-CAM7). As shown in Fig. 2c , only the GVLVGVALV analog was cross-recognized by the CEA694L2 peptidespeciWc no. R1 T-cell clone, thus suggesting the potential capacity to recognize CEACAM3-, CEACAM4-, and CEACAM5-derived antigens.
These results show that the clone CEA 694-702 L2 no. R1 is cross-reactive to native and high HLA-A2 aYnity peptide analogs with intermediate to low-functional avidity.
Tumor-cell recognition by CEA-speciWc CTL clones
We next assessed the ability of peptide analog-speciWc cloned CD8
+ T-cells to recognize CEA-expressing human tumor cell lines. We Wrst evaluated the expression levels of CEACAM3, CEACAM4, and CEACAM5 in the tumor cells by semi-quantitative RT-PCR. As shown in Fig. 3a , CEACAM3 and CEACAM4 were found to be selectively expressed by granulocytes isolated from human PBMC [18, 22] . None of the epithelial cell lines tested detectably expressed those transcripts by semi-quantitative PCR. In contrast, several epithelial tumor cell lines expressed CEA-CAM5 mRNA especially SW403, KATOIII, and LOVO. The expression in those cells was higher or equal to -actin expression levels. CEACAM5 was undetectable in HCT-116 and SW480. Other cell lines such as SW620, COLO201, SW1116, and T84 expressed relatively low levels. Similar results were found when the levels of protein expression were evaluated by Xow cytometry with a pan-CEA-speciWc antibody (data not shown).
We then assessed the ability of no. R1 T CTL clone to recognize and lyse tumor cell lines. As shown in Fig. 3b , the clone was able to recognize and eYciently kill all HLA-A*0201 tumor cell lines pulsed with the native CEA [694] [695] [696] [697] [698] [699] [700] [701] [702] peptide. However, in the absence of exogenously added peptide, it only killed the SW403 colon cancer cell line. Close to background lysis levels were observed for KATO III (HLA-A2 + ), COLO201 (HLA-A2 + ), and SW620 (HLA-A2 + ). Importantly, SW1116 (HLA-A2 + ), the cell line from which the peptide CEA 694-702 was eluted, was not recognized. A similar deWciency of recognition and lysis was observed with the T84 and SW480 tumor cell lines. As expected, background levels of lysis were present with the cell lines LOVO (HLA-A2 ¡ ), Me 290 (HLA-A2 melanoma cell line, CEA ¡ ), and K562 (NK sensitive). We further evaluated the speciWcity of recognition of the SW403 cell line using a cold-target inhibition of cell lysis assay. As CD8+ T-cell clone in a chromium release assay. Pulsed targets were loaded with 1 g/ml of CEA 694-702 peptide. c Peptide-dependent recognition of SW403 colon cancer cell line assessed by cold-target inhibition. The ratio cold : hot was 10:1. Cold targets were T2-cells pulsed with either 1 g/ml of CEA 694-702 peptide or 1 g/ml of FluMA 58-66 peptide depicted in Fig. 3c , the recognition of SW403 by the clone CEA694L2 no. R1 was signiWcantly reduced by the presence of excess cold-targets (T2-cells) pulsed with CEA 694-702 native peptide. In contrast, cold-targets pulsed with an irrelevant peptide did not inhibit lysis of SW403, thus conWrming the peptide speciWcity of the observed tumor cell lysis. We also tested the recognition of HLA-A*0201 positive granulocytes by both the T-cell clone and polyclonal CEA694L2-speciWc CTLs in cytolytic assays. However, no evidence of T-cell recognition could be detected even in the presence of exogenously added native CEA 694-702 peptide (data not shown).
Overall, these results show that peptide CEA 694-702 can be processed and presented by tumor cells lines expressing HLA-A*0201 and high levels of CEACAM5.
Analysis of CEA 694-702 -speciWc CD8+ T-cell responses in colon cancer patients
We next addressed the existence of CEA 694-702 -speciWc CD8 + T-cell responses in a group of HLA-A2 + colon cancer patients. To assess the possible existence of high frequencies of CEA 694-702 -speciWc CD8 + T-cells, we labeled PBMCs from three HLA-A*0201 colon cancer patients with A2/CEA 694-702 L2 multimers. As summarized in Table 3 , none of the three cancer patients had detectable CEA694L2-speciWc CD8 + T-cells ex vivo. However, after a single stimulation of PBMCs with peptide CEA694L2, CEA694L2-speciWc CD8 + T-cells signiWcantly expanded in two of three patients to numbers as high as 3% of the total CD8 + T-cell population. The patient that failed to respond to the stimulation protocol also showed no detectable expansion of FluMA 58-66 peptide-speciWc CD8 + T-cells, suggesting low responsiveness of the T-cells. PBMCs stimulated with the immunogenic HLA-A*0201-restricted peptide NY-ESO-1 157-165 did not generate CEA694L2-speciWc CD8 + T-cells, demonstrating the antigen speciWcity of the induced T-cells (Fig. 4a) .
These results reveal the presence of CEA 694-702 -speciWc T-cells in the peripheral blood of cancer patients that can be mobilized and expanded using peptide analogs of higher HLA-A*0201 aYnity.
We further extended the study of these in vitro responses by CEA694L2 multimer-speciWc guided cell sorting and establishment of CD8 + T-cell clones by limiting dilution. These clones were then characterized for their cross-recognition of the native peptide. As shown in Fig. 4b , a surprisingly low eYciency of antigen recognition was recorded for the great majority of the T-cell clones evaluated in native peptide titration assays. They attained half maximal lysis with concentrations of native CEA 694-702 peptide that were approximately one log higher than those required by CTL clones isolated from PBMC of healthy donors (Fig. 2b) . At the same time, these series of T-cell clones obtained from cancer patients displayed a marked high level of recognition eYciency of the CEA694L2 analog peptide. The reduced cross-recognition activity of these CTL clones and their lower lytic eYciency forecasted a reduced or complete abrogation of tumor-cell recognition. Cytolytic assays were performed with multimer-sorted bulk T-cell populations and several T-cell clones of diVerent avidities (Fig. 4c) . The results obtained conWrmed our expectations on the potential failure of the CTL clones generated from cancer patients, as these CTL were unable to recognize tumor cells expressing CEA antigen even when treated with IFN-for 72 h, a treatment commonly used to increase HLA class-I expression [35] .
Discussion
We have addressed the potential immunogenicity of a CEA-derived non-apeptide identiWed 6 years ago as an HLA-A2 binding peptide [33] . The promise of this peptide as a bona Wde tumor-associated antigen stemmed from the evidence that the peptide is naturally processed. Indeed, the peptide was found via the biochemical analysis of the pool of peptides eluted from MHC class-I molecules that had been puriWed from an HLA-A2 + colorectal carcinoma cell line. Our experimental analysis lead to the following conclusions: (1) the native peptide binds weakly to the HLA-A2 molecule and is poorly immunogenic in an in vitro culture system, (2) introduction of the two major anchors for HLA-A2 substantially improves both binding to HLA-A2 and in vitro immunogenicity, (3) peptide analog-speciWc CTL clones generated from healthy donor lymphocytes can be tumor reactive and display intermediate functional TCR avidity, and (4) peptide analog-speciWc CTL generated from colorectal carcinoma patients have a signiWcantly lower TCR avidity for cross-recognition of the native CEA 694-702 peptide and fail to recognize tumor cells expressing both HLA-A2 and CEA. In contrast to the so-called direct immunology approach to identify CTL-deWned tumor antigens [14, 42] , where tumor cell lysis by CTLs already proves that naturally processed antigen is recognized and can trigger CTLs, both reverse immunology [43] and biochemical methods for identiWcation of T-cell epitopes [29, 33] require proof that the hypothetical antigenic candidates are naturally processed and immunogenic. In this regard, for several tumor antigen candidates, contradictory data have been reported concerning peptide immunogenicity, presentation by tumor cells, and tumor cell peptide-speciWc CTL tumor recognition [2, 4, 7, 19, 27, 31, 32, 41, 44] . Therefore, it is critical for the appropriate validation of tumor-derived CD8+ Tcell epitopes that reproducible data on the antigen processing, immunogenicity, functional performance of induced CTLs, and tumor cell recognition are provided.
From the list of eluted peptides, reported by Shirle et al., the previously unknown peptide CEA 694-702 was described [33] . Surprisingly, other previously known CEA HLA-A*0201 CD8 + peptides were not detected, raising doubts concerning the eYciency of their antigen processing. However, peptides may be present at too low numbers, or other reasons may account for lack of peptide identiWcation by biochemical analysis of material obtained with acid elution.
Our Wndings pose a paradox: that a peptide with low aYnity for HLA-A*0201 and forming unstable complexes could be successfully identiWed from the mixture of MHC class-I eluted peptides, in both a tumor cell line and a tumor tissue fragment [33] . Nevertheless, successful identiWcation of naturally processed peptides with low aYnity to HLA-A2 molecules has been reported [36] . It is conceivable that the original eluted fraction from which the peptide was identiWed was composed of a mix of closely related peptide analogs, which provided fragment signals leading to the CEA 694-702 sequence prediction. However, screening for HLA-A*0201-binding natural CEA 694-702 analogs in human protein databases consistently provided CEA family-related protein-derived peptides (CEACAM1 436-444 : GVVALVALI, CEACAM3 159-167 : GVLGVGALV, CEACAM4 159-167 : GVLGVGALV, CEACAM5 694-702 : GVLVGVALI, CEA-CAM6 336-344 : GVLARVALI, CEACAM7 257-265 : GVLAG-MALI, and CEACAM8 341-349 : GVLARVALI). Among these, only the GVLVGVALI and GVLVGVALV peptides were cross-recognized by the CEA694L2 no. R1 clone Fig. 4 Immunogenicity of the CEA 694-702 L2 peptide analog in HLA-A*0201 colon cancer patients and tumor reactivity of CD8+ T-cell clones. a PBMCs from three HLA-A2 colon cancer patients were stimulated with 10 g/ml of peptide and cultured for 10 days in 1,000 IU/ml IL-2. FluMA 58-66 and NY-ESO-1 157-165 peptides were used as controls of peptide-speciWc CTL induction. Cells were labeled with the indicated A2 multimer and anti-CD8 mAb. Data is summarized in Table 3 . b CEA 694-702 WT and CEA 694-702 L2 peptide recognition eYciency of the 18 patient-derived CTL clones generated from A2/CEA 694-702 multimers-guided cell sorting and limiting dilution. (Fig. 2c) . Other variants were not detectably cross-recognized and are predicted as very weak binders to HLA-A*0201 (Table 2) .
Furthermore, the semi-quantitative PCR analysis suggests that CEACAM5 is the likely source of the peptide present in the peptide elution pool, as all colon epithelial tumor cells, including the SW1116 cell line, expressed detectable amounts of the CEACAM5 cDNA. Moreover, CEACAM3 and CEACAM4, which code for cross-recognized peptides with GVLVGVALI, are not expressed by tumor cell lines (Fig. 3a) . Alternatively, it can be hypothesized that the oV-rate of the low-aYnity peptide CEA694 is compensated by a high rate of antigen synthesis, proteolysis, and derived peptide presentation at the cell surface [28, 46] . It is interesting to note that the CEA694-702 epitope is located at the carboxyl terminus of CEACAM5, which ensures its release in the cytoplasm by proteasomal degradation [11] .
The expression of CEACAM5 in epithelial tissues may likely result in the induction of both central and peripheral tolerance [17] , as has been previously described for other tumor-associated antigens, e.g., p53, gp100 [15, 24] . Our Wndings are in agreement with the hypothesis that tolerance to CEA antigen may exist in humans. First, the immunogenic CEA peptide analogs display diVerential CTL induction eYciency, as their relative immunogenicity does not strictly correlate with their relative HLA-A*0201-binding capacity. Second, the peptide-speciWc CD8 + T-cell clones all had low to intermediate TCR avidities irrespective of whether they had been induced by CEA694L2, CEA694V9, or CEA694L2V9. In addition, clones derived by stimulation with the CEA694V9 and CEA694L2V9 had a very limited proliferation capacity. Moreover, other independent studies with diVerent CEACAM5-derived peptides have also reported low to intermediate TCR avidities [47] . Third, CD8 + T-cell clones generated from colon cancer patients had in general lower avidity toward the CEA 694-702 peptide than CD8+ T-cell clones generated from human healthy donors and were unable to recognize CEACAM5 expressing tumor cells even when treated with IFN-. These results suggest that tumor-derived CEA may drive in parallel both the expansion of CEA 694-702 -speciWc CD8+ T-cells in vivo and the deletion of T-cells with relatively high-TCR avidity. The fact that these patients often present high levels of CEA antigen in their serum might contribute to these processes.
Altogether, the present Wndings raise serious concerns on the eYcacy of immunological tumor surveillance provided by the CEA 694-702 -speciWc CD8 + T-cells; particularly because the native epitope is poorly immunogenic, the speciWc T-cell repertoire induced by peptide analogs shows low avidity in colon cancer patients and fails to recognize allogenic tumor cells expressing CEACAM5.
